Aclaris Therapeutics (ACRS) CBO has 15,980 shares withheld for taxes

Rhea-AI Filing Summary

Aclaris Therapeutics Chief Business Officer James Loerop reported an automatic share withholding related to equity compensation. On February 1, 2025, the issuer withheld 15,980 shares of common stock at $2.48 per share to cover his tax obligations upon restricted stock unit vesting.

After this transaction, Loerop beneficially owned 102,773 shares of Aclaris common stock in direct ownership. The filing is an amendment that corrects the previously reported number of shares withheld, which will change the reported beneficial ownership amounts in later filings.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Loerop James

Role Chief Business Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	15,980	$2.48	$40K

Holdings After Transaction: Common Stock — 102,773 shares (Direct)

Footnotes (1)

1. The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. This amendment is being filed to correct the number of shares that were withheld by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units previously reported. This adjustment will affect the amount of securities beneficially owned following the reported transaction in subsequent filings.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Loerop James

(Last) (First) (Middle)

C/O ACLARIS THERAPEUTICS, INC.

701 LEE ROAD, SUITE 103

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ ACRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/01/2025		F(1)		15,980	D	$2.48	102,773(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.

2. This amendment is being filed to correct the number of shares that were withheld by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units previously reported. This adjustment will affect the amount of securities beneficially owned following the reported transaction in subsequent filings.

	/s/ Matthew Rothman, Attorney-in-Fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ACRS Chief Business Officer James Loerop report?

James Loerop reported an automatic share withholding, not an open-market trade. On February 1, 2025, Aclaris Therapeutics withheld 15,980 shares of common stock to satisfy his tax obligations from vesting restricted stock units, as disclosed in this amended Form 4 filing.

How many ACRS shares were withheld for taxes in this Form 4?

The company withheld 15,980 shares of Aclaris Therapeutics common stock. These shares were retained by the issuer to cover James Loerop’s tax withholding obligations triggered by the vesting and settlement of his restricted stock units, according to the reported transaction details.

What price per share is reported for the ACRS tax withholding transaction?

The Form 4 shows a transaction price of $2.48 per share for the withheld stock. This price applies to the 15,980 Aclaris Therapeutics common shares used to satisfy Chief Business Officer James Loerop’s tax obligations on vested restricted stock units.

How many ACRS shares does James Loerop own after the reported transaction?

Following the tax withholding transaction, James Loerop beneficially owned 102,773 shares of Aclaris Therapeutics common stock. The filing specifies this amount as directly held, reflecting his updated post-transaction ownership position as of the reported date.

Why is this ACRS Form 4 labeled as an amendment?

The Form 4 is an amendment because it corrects the number of shares previously reported as withheld for taxes. Aclaris Therapeutics states this adjustment will affect the amounts shown as beneficially owned in subsequent filings for Chief Business Officer James Loerop.

Does the ACRS Form 4 indicate an open-market sale by the insider?

No, the filing describes issuer share withholding for taxes rather than an open-market sale. Aclaris Therapeutics retained 15,980 shares from restricted stock unit vesting to satisfy James Loerop’s tax obligations, which is a common administrative transaction for equity awards.